Key Highlights

  • Intellia shares are trading 5.82% higher at $12.97 on Wednesday, October 28, 2026.
  • Short interest was 44,435,219 shares as of October 15, 2026, about 31.7% of shares outstanding (calculated).
  • Days to cover stood at 6.45, based on average daily volume of about 6.9 million shares.
  • The FDA set a March 10, 2027 target action date for lonvo-z with priority review.
  • Cash and marketable securities were $628.4 million at June 30, 2026, funding operations into 2028.

Intellia Move: Why Is a Heavily Shorted Gene-Editing Stock Trading 6% Higher?

Intellia (NASDAQ:NTLA) shares are trading 5.82% higher at $12.97 on Wednesday, October 28, 2026, an implied prior close of about $12.26 (calculated). No company release is dated today. The latest dated items are the appointment of a new chief medical officer announced on October 13 and the FDA acceptance of its first license application on September 8.

Intellia develops genome-editing medicines based on CRISPR/Cas9 and delivers them directly inside the body. Its main program, lonvo-z, is a one-time treatment for hereditary angioedema (HAE), a rare condition that causes recurring swelling attacks. At today's price, the 140.13 million shares outstanding imply a market capitalization near $1.82 billion (calculated).

Short Interest: What Does 31.7% of Shares Sold Short Mean for the Stock?

Short-interest data for the settlement date of October 15, 2026 show 44,435,219 shares sold short, down 675,294 from the prior period. That equals about 31.7% of shares outstanding (calculated), and the figure is not a float-based percentage. Days to cover were 6.45.

When a large share of the stock is sold short, buying by short sellers closing positions can add to a rally, while new short selling can add pressure on declines.

One research firm rates the stock underweight with an $8 price target, against a consensus average near $23.

Lonvo-z Application: How Strong Is the HAELO Evidence Behind the March 2027 Date?

On September 8, 2026, the FDA accepted the biologics license application for lonvo-z and granted priority review, setting a target action date of March 10, 2027. The agency said it does not currently plan an advisory committee meeting. If approved, lonvo-z would be the first in vivo CRISPR-based therapy and the only one-time HAE treatment.

The application rests on the 80-patient Phase 3 HAELO trial, in which a single 50 mg dose cut mean monthly attacks by 87% versus placebo over weeks 5 to 28. Over six months, 62% of treated patients were attack-free and off HAE therapy, versus 11% on placebo. No serious adverse events occurred in the lonvo-z arm.

Intellia Finances and Nex-z: Does the Cash Position Cover the Cost of the Build-Out?

For the second quarter ended June 30, 2026, Intellia reported a net loss of $106.6 million, or $0.80 per share. Research and development expense fell to $82.6 million from $97.0 million, while general and administrative expense rose to $37.8 million from $27.2 million on commercial preparation. Collaboration revenue fell to $7.7 million from $14.2 million, mainly on lower revenue from Regeneron (NASDAQ:REGN).

Cash and marketable securities were $628.4 million after about $195 million in net proceeds from an April 2026 offering. A September 4 debt facility with OrbiMed provides up to $400 million, of which $75 million was funded upfront. Enrollment has restarted in the MAGNITUDE and MAGNITUDE-2 trials of nex-z, with MAGNITUDE-2 enrollment completion expected in the second half of 2026.

What to Watch Next: Settlement Data, Third-Quarter Results and the March 10, 2027 Decision

The next short-interest figure covers the October 30 settlement date and is due November 10. Third-quarter results are estimated for around November 9, and the FDA target action date for lonvo-z is March 10, 2027. Management has planned a United States launch in the first half of 2027 if approved.